CSIMarket
 


Adaptive Biotechnologies Corporation  (ADPT)
Other Ticker:  
 

Adaptive Biotechnologies's Working Capital Ratio

ADPT's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Working Capital Ratio deteriorated to 4.67 below Adaptive Biotechnologies's average Working Capital Ratio.

Within Biotechnology & Pharmaceuticals industry 94 other companies have achieved higher Working Capital Ratio than Adaptive Biotechnologies in third quarter 2023. While Working Capital Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 548 to 951.

Explain Working Capital Ratio
How much in Current Assets ADPT´s has?
What is the value of ADPT´s Current Liabilities?


ADPT Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -10.31 % -14.47 % -21.7 % -3.53 % -15.01 %
Y / Y Current Assets Change -22.88 % 8.72 % 19.62 % 39.58 % 20.85 %
Working Capital Ratio MRQ 4.67 5 5.56 5.12 5.43
ADPT's Total Ranking # 951 # 548 # 720 # 134 # 1073
Seq. Current Liabilities Change -2.14 % 5.81 % -17.93 % 5.55 % -6.68 %
Seq. Current Assets Change -8.72 % -4.89 % -10.82 % -0.4 % 28.68 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 95
Healthcare Sector # 444
Overall Market # 951


Working Capital Ratio Statistics
High Average Low
49.67 8.01 1.58
(Sep 30 2019)   (Dec 31 2014)




Financial Statements
Adaptive Biotechnologies's Current Liabilities $ 93 Millions Visit ADPT's Balance sheet
Adaptive Biotechnologies's Current Assets $ 435 Millions Visit ADPT's Balance sheet
Source of ADPT's Sales Visit ADPT's Sales by Geography


Cumulative Adaptive Biotechnologies's Working Capital Ratio

ADPT's Working Capital Ratio for the trailling 12 Months

ADPT Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -10.31 % -14.47 % -21.7 % -3.53 % -15.01 %
Y / Y Current Assets TTM Growth -22.88 % 8.72 % 19.62 % 39.58 % 20.85 %
Working Capital Ratio TTM 5.08 5.27 4.97 4.51 4.11
Total Ranking TTM # 722 # 726 # 651 # 106 # 447
Seq. Current Liabilities TTM Growth -2.14 % 5.81 % -17.93 % 5.55 % -6.68 %
Seq. Current Assets TTM Growth -8.72 % -4.89 % -10.82 % -0.4 % 28.68 %


On the trailing twelve months basis In spite of the year on year decrease in ADPT's Current Liabilities to $93.30 millions, cumulative Working Capital Ratio to 5.08 above the company average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 95 other companies have achieved higher Working Capital Ratio than Adaptive Biotechnologies. While Working Capital Ratio overall ranking has improved so far to 722, from total ranking during the twelve months ending second quarter 2023 at 726.

Explain Working Capital Ratio
How much in Current Assets ADPT´s has?
What is the value of ADPT´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 96
Healthcare Sector # 434
Within the Market # 722


trailing twelve months Working Capital Ratio Statistics
High Average Low
7.63 4.86 2.28
(Sep 30 2020)   (Jun 30 2015)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Ambrx Biopharma Inc   12.80 $ 233.818  Millions$ 18.268  Millions
Replimune Group Inc   12.76 $ 508.175  Millions$ 39.832  Millions
Allogene Therapeutics inc   12.58 $ 473.454  Millions$ 37.636  Millions
Scholar Rock Holding Corp  11.70 $ 228.465  Millions$ 19.530  Millions
Kymera Therapeutics Inc   11.66 $ 375.694  Millions$ 32.219  Millions
Protara Therapeutics Inc   11.49 $ 77.813  Millions$ 6.775  Millions
Tarsus Pharmaceuticals Inc   11.15 $ 259.277  Millions$ 23.249  Millions
Inhibrx Inc   10.76 $ 363.297  Millions$ 33.760  Millions
Vir Biotechnology Inc   10.72 $ 1,769.176  Millions$ 165.050  Millions
Ikena Oncology Inc   10.41 $ 200.634  Millions$ 19.271  Millions
Invivyd Inc   10.08 $ 270.103  Millions$ 26.791  Millions
Cardiff Oncology inc   10.07 $ 83.905  Millions$ 8.330  Millions
Black Diamond Therapeutics Inc   9.76 $ 147.049  Millions$ 15.066  Millions
Argenx se  9.75 $ 4,123.737  Millions$ 422.993  Millions
Autolus Therapeutics Plc  9.62 $ 308.382  Millions$ 32.049  Millions
Biontech Se  9.43 $ 21,870.576  Millions$ 2,318.960  Millions
Solid Biosciences Inc   9.38 $ 148.346  Millions$ 15.816  Millions
Turnstone Biologics Corp   9.08 $ 118.835  Millions$ 13.081  Millions
Jasper Therapeutics Inc   8.84 $ 105.218  Millions$ 11.906  Millions
Fate Therapeutics Inc   8.81 $ 364.174  Millions$ 41.333  Millions
Springworks Therapeutics Inc   8.60 $ 432.383  Millions$ 50.283  Millions
Century Therapeutics inc   8.50 $ 173.703  Millions$ 20.435  Millions
Atyr Pharma Inc   8.33 $ 107.298  Millions$ 12.881  Millions
Pluri Inc   8.16 $ 35.258  Millions$ 4.322  Millions
Monte Rosa Therapeutics Inc   8.09 $ 182.911  Millions$ 22.609  Millions
Senti Biosciences Inc   7.81 $ 79.007  Millions$ 10.114  Millions
Tracon Pharmaceuticals Inc   7.72 $ 8.340  Millions$ 1.080  Millions
Halozyme Therapeutics Inc   7.63 $ 879.006  Millions$ 115.185  Millions
Tscan Therapeutics Inc   7.56 $ 217.567  Millions$ 28.775  Millions
C4 Therapeutics Inc   7.39 $ 223.686  Millions$ 30.271  Millions

Date modified: 2023-11-12T11:08:54+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com